Summary
In chronic heart failure diuretic drugs improve central hemodynamic variables and cardiac pumping secondary to altered plasma and extracellular volumes; humoral markers of these changes include increased plasma renin and aldosterone levels. The latter increases are maximal over the first week but decline with chronic therapy. The plasma alpha-ANP levels show a reciprocal effect; these data are compatible with a rapid contraction of the plasma volume which is sustained during chronic therapy.
The acute hemodynamic actions of diuretic agents reflect both immediate and direct vascular actions and also effects secondary to diuresis (volume redistribution). At rest substantial reductions in pulmonary “wedge” pressure (−29%), with a consequent fall in cardiac output (−10%), are described. Total systemic vascular resistance initially increases but “reverse autoregulation” over subsequent weeks returns this elevation gradually towards control values. Tolerance to these initial hemodynamic effects does not occur with maintained therapy; moreover, echocardiographic markers of contractility and exercise capacity may increase. The early venodilator effects of diuretic drugs can be attributed to prostaglandin release and the initial pressor actions to activation of the renin angiotensin system; these vascular actions may have limited relevance to long-term beneficial effects on hemodynamics. Direct pulmonary vasodilation and improved pulmonary compliance remain an interesting finding. Although most patients are both symptomatically and hemodynamically improved at rest, the actions during exercise are more varied. Some individuals with severely impaired left ventricular function show little hemodynamic improvement, whereas those with milder dysfunction usually benefit; in the main this is probably related to the latter being on a steeper cardiac function curve. The impact of diuretic therapy on the underlying disease process is unclear; however, there is little convincing evidence of remodelling or improvement in intrinsic performance (as distinct from that induced by altered loading conditions).
Similar content being viewed by others
References
Shah S, Khatri I, Freis D. Mechanism of antihypertensive effect of thiazide diuretics.Am Heart J 1978;95:611–618.
Tobian L. Hypertension and the kidney.Arch Intern Med 1974;133:959–967.
Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide.Circulation 1960;21:21–27.
Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the anti-hypertensive effect of chlorothiazide.Circulation 1959;20:1020–1036.
Tarazi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension.Circulation 1970;16:709–717.
Bourgoignie JJ, Catanzaro FJ, Perry HM. Renin-angiotensin-aldosterone system during chronic thiazide therapy of benign hypertension.Circulation 1968;37:2793–2795.
Lijnen P, Fagard R, Staessen J, Amery A. Hormonal effects of the diuretic xipamide in healthy men.Cardiovasc Drugs Ther 1991;5:741–746.
Dikshit K, Vyden JK, Forrester JS, et al. Renal and extrarenal haemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction.N Engl J Med 1973;88:1087–1090.
Nelson GIC, Ahuja RC, Silke B, et al. Haemodynamic effects of frusemide and its influence on repetitive rapid volume loading in acute myocardial infarction.Eur Heart J 1983;4:706–711.
Verma SP, Silke B, Reynolds G, et al. Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure.Br J Clin Pharmacol 1987;24:21–32.
Taylor SH, Storstein L. Diuretics in the treatment of heart failure.Herz 1983;8:11–22.
Johnston GD, Nicholls DP, Leahey WJ, Finch MB. The effects of captopril on the acute vascular responses to frusemide in man.Clin Sci 1983;65:359–363.
Johnston GD, Nicholls DP, Kondowe GB, Finch MB. Comparison of the acute vascular effects of frusemide and bumetanide.Br J Clin Pharmacol 1986;21:359–364.
Lal S, Murtagh JG, Pollock AM, et al. Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressure.Br Heart J 1969;31:711–717.
Davidson RM, Goldman J, Whalen RE, Wallace AG. Haemodynamic effects of furosemide in acute myocardial infarction.Circulation 1971;44:157–158.
Kiely J, Kelly DT, Taylor DR, Pitt B. The role of furosemide in the treatment of left ventricular dysfunction associated with acute myocardial infarction.Circulation 1973;48:581–587.
Mond H, Hunt D, Sloman G. Hemodynamic effects of frusemide in patients suspected of having acute myocardial infarction.Br Heart J 1974;36:44–53.
Biddle TL, Yu PN. Effect of furosemide on haemodynamics and lung water in acute pulmonary oedema secondary to myocardial infarction.Am J Cardiol 1979;43:86–90.
Nelson GIC, Silke B, Ahuja RC, et al. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart failure following myocardial infarction.Lancet 1983;1:730–732.
Franciosa JA, Silverstein SR, Wilen M. Hemodynamic effects of nitroprusside and furosemide in left ventricular failure.Clin Pharmacol Ther 1982;32:62–69.
Bennett WM, McDonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis?Clin Pharmacol Ther 1977;22(5):499–504.
Austin SM, Schreiner BF, Kramer DH, et al. The acute hemodynamic effects of ethacrynic acid and furosemide in patients with chronic post-capillary pulmonary hypertension.Circulation 1976;53:364–369.
Hesse B, Nielsen I, Lund-Jacobsen H. The early effects of intravenous furosemide on central haemodynamics, venous tone, and plasma renin activity.Clin Sci Mol Med 1975;49:551–555.
Valette H, Hebert JL, Apoil E. Acute haemodynamic effects of a single intravenous dose of piretanide in congestive heart failure.Eur J Clin Pharmacol 1983;24:163–167.
Valette H, Hebert JL, Raffestin B, et al. Comparison of hemodynamic effects of furosemide and piretanide in normovolemic patients.J Cardiovasc Pharmacol 1990;2:103–111.
Valette H, Duhaze P, Apoil E. Plethysmographic study with furosemide and piretanide in healthy volunteers (letter).Br J Clin Pharmacol 1979;7:219.
Fiehring H, Achhammer I. Influence of 10 mg torasemide i.v. and 20 mg furosemide i.v. on the intracardiac pressures in patients with heart failure at rest and during exercise.Prog Pharmacol Clin Pharmacol 1990;8(1):97–104.
Isbary J, Achhammer I, Wetzels E. The influence of 20 mg torasemide i.v. and 20 mg furosemide i.v. on hemodynamics and diuresis in patients with high grade left heart failure.Prog Pharmacol Clin Pharmacol 1990;8(1):137–146.
Langbehn A-F, Achhammer I, Bölke T. Acute hemodynamic effects of 20 mg torasemide and 20 mg furosemide given intravenously to patients with congestive heart failure.Prog Pharmacol Clin Pharmacol 1990;8(1):147–155.
Podszus T, Piesche L. Effect of torasemide on pulmonary and cardiac haemodynamics after oral treatment of chronic heart failure.Prog Pharmacol Clin Pharmacol 1990;8(1):157–166.
Ziacahi V, Rossi A, Lomanto B. Modificazioni emodinamiche indoite dalla bumetanide endovenosa nello scompenso congestizio (Haemodynamic modifications induced by intravenous bumetanide in congestive heart failure).G Ital Cardiol 1981;11:104–109.
Haerer W, Bauer U, Sultan N, et al. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure—a placebo-controlled trial.Cardiovasc Drugs Ther 1990;4:515–522.
Cheitlin MD, Byrd R, Benowitz N, et al. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics.Cardiovasc Drugs Ther 1991;5:719–726.
Stauch M, Stiehl L. Controlled double-blind clinical trial of the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure.Prog Pharmacol Clin Pharmacol 1990;8(1):121–126.
Oversohl K, Mehrabian G, Hanisch M, Schmitz H. Muzolimine as monotherapy in the treatment of patients with congestive heart failure.Z Kardiol 1985;74(Suppl 2):27–31.
Dalla Volta S, Scognamiglio R, Sorbio MD, et al. Effect of muzolimine in aortic insufficiency with different levels of left ventricular function.Z Kardiol 1985;74(Suppl 2):13–18.
Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.Lancet 1988;1:255–259.
Sharpe N, Murphy J, Smith H, Hannan S. Preventive treatment of asymptomatic left ventricular function following myocardial infarction.Eur Heart J 1990;11(Supp B):147–156.
Düsing R, Piesche L. Second line therapy of congestive heart failure with torasemide.Prog Pharmacol Clin Pharmacol 1990;8(1):105–120.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silke, B. Central hemodynamic effects of diuretic therapy in chronic heart failure. Cardiovasc Drug Ther 7 (Suppl 1), 45–53 (1993). https://doi.org/10.1007/BF00877957
Issue Date:
DOI: https://doi.org/10.1007/BF00877957